CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma

Haematologica

Volumn 96, Issue 10, 2011, Pages 1557-1559

  Such, Esperanza ^a   Cervera, José ^a   Terpos, Evangelos ^b   Bagán, José V ^c,d   Avaria, Amparo ^a   Gómez, Inés ^a   Margaix, María ^c   Ibañez, Mariam ^a   Luna, Irene ^a   Cordón, Lourdes ^a   Roig, Mónica ^a   Sanz, Miguel A ^a,d   Dimopoulos, Meletios A ^b   de la Rubia, Javier ^a,e  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c University General Hospital of Valencia   (Spain)

^d UNIVERSITY OF VALENCIA   (Spain)

^e UNIVERSIDAD CATÓLICA DE VALENCIA SAN VICENTE MÁRTIR   (Spain)

Author keywords

Bisphosphonates; CYP2C8; Multiple myeloma; ONJ

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CYTOCHROME P450 2C8;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; CYP2C8 GENE; DNA POLYMORPHISM; FEMALE; GENE; GENE FREQUENCY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; RISK ASSESSMENT; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ARYL HYDROCARBON HYDROXYLASES; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 80053624145     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.042572     Document Type: Article

References (17)

1. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, et al. Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA. 2001;98(20): 11581-11586.
2. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351(18):1860-1873.
3. Terpos E, Sezer O, Croucher PI, García-Sanz R, Boccadoro M, San Miguel J, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol. 2009;20(8):1303-1317.
4. Badros A, Terpos E, Katodritou E, Goloubeva O, Kastritis E, Verrou E, et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol. 2008;26(36):5904-5909.
5. Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med. 2005;34(2):120-123.
6. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica. 2006;91(7): 968-971.
7. Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, et al. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev. 2010;(3): CD003188.
8. Cafro AM, Barbarano L, Nosari AM, D'Avanzo G, Nichelatti M, Bibas M, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid. Clin Lymphoma Myeloma. 2008;8(2):111-116.
9. Sarasquete ME, García-Sanz R, Marín L, Alcoceba M, Chillón MC, Balanzategui A, et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood. 2008;112(7):2709-2712.
10. Rodríguez-Antona C, Niemi M, Backman JT, Kajosaari LI, Neuvonen PJ, Robledo M, et al. Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J. 2008;8(4):268-277.
11. Speed WC, Kang SP, Tuck DP, Harris LN, Kidd KK. Global variation in CYP2C8- CYP2C9 functional haplotypes. Pharmacogenomics J. 2009;9(4):283-290.
12. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749-757.
13. Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia. 2009;23(9): 1545-1556.
14. Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
15. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50(3):163-170.
16. Gray RJ. A class of K-sample test for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
17. Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, et al. Longitudinal Cohort Study of Risk Factors in Cancer. Patients of Bisphosphonate-Related Osteonecrosis of the Jaw. J Clin Oncol 27(32):5356-5362.